{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:59:20Z","timestamp":1794373160323,"version":"4.9.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41591-025-03688-6","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T05:04:30Z","timestamp":1745903070000},"page":"2768-2777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":false,"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1464-7158","authenticated-orcid":false,"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yandong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9874-1314","authenticated-orcid":false,"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-0551","authenticated-orcid":false,"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"3688_CR1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"3688_CR2","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457\u20132467 (2012).","journal-title":"Cancer Res."},{"key":"3688_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc2030638","volume":"384","author":"AH Nassar","year":"2021","unstructured":"Nassar, A. H., Adib, E. & Kwiatkowski, D. J. Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type. N. Engl. J. Med. 384, 185\u2013187 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3688_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.lungcan.2023.02.021","volume":"178","author":"MG Frost","year":"2023","unstructured":"Frost, M. G. et al. KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): characteristics, treatment patterns and overall survival from a Danish nationwide observational register study. Lung Cancer 178, 172\u2013182 (2023).","journal-title":"Lung Cancer"},{"key":"3688_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.lungcan.2021.02.005","volume":"154","author":"M Sebastian","year":"2021","unstructured":"Sebastian, M. et al. KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer 154, 51\u201361 (2021).","journal-title":"Lung Cancer"},{"key":"3688_CR6","doi-asserted-by":"publisher","first-page":"S218","DOI":"10.1016\/j.annonc.2021.05.007","volume":"32","author":"M Salem","year":"2021","unstructured":"Salem, M. et al. O-3 characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies. Ann. Oncol. 32, S218 (2021).","journal-title":"Ann. Oncol."},{"key":"3688_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BCJ20220234","volume":"480","author":"W Kolch","year":"2023","unstructured":"Kolch, W., Berta, D. & Rosta, E. Dynamic regulation of RAS and RAS signaling. Biochem. J. 480, 1\u201323 (2023).","journal-title":"Biochem. J."},{"key":"3688_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3688_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter, J. C. et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13, 1325\u20131335 (2015).","journal-title":"Mol. Cancer Res."},{"key":"3688_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 6, 316\u2013329 (2016).","journal-title":"Cancer Discov."},{"key":"3688_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"3688_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172, 578\u2013589.e517 (2018).","journal-title":"Cell"},{"key":"3688_CR13","doi-asserted-by":"crossref","unstructured":"Mok, T. S. K. et al. KRYSTAL-12: phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. J. Clin. Oncol. 42, LBA8509 (2024).","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509"},{"key":"3688_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet 401, 733\u2013746 (2023).","journal-title":"Lancet"},{"key":"3688_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih, M. G. et al. Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23, 115\u2013124 (2022).","journal-title":"Lancet Oncol."},{"key":"3688_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 388, 44\u201354 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3688_CR17","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389, 2125\u20132139 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3688_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger, R. et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. Cancer Discov. 14, 982\u2013993 (2024).","journal-title":"Cancer Discov."},{"key":"3688_CR19","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1158\/2159-8290.CD-24-0006","volume":"14","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. D3S-001, a KRAS G12C inhibitor with rapid target engagement kinetics, overcomes nucleotide cycling, and demonstrates robust preclinical and clinical activities. Cancer Discov. 14, 1675\u20131698 (2024).","journal-title":"Cancer Discov."},{"key":"3688_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan, M. B. et al. KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy. Cell Rep. 39, 110993 (2022).","journal-title":"Cell Rep."},{"key":"3688_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue, J. Y. et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature 577, 421\u2013425 (2020).","journal-title":"Nature"},{"key":"3688_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio, V. et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov. 10, 1129\u20131139 (2020).","journal-title":"Cancer Discov."},{"key":"3688_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3688_CR24","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3688_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","volume":"31","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial. Nat. Med. 31, 894\u2013900 (2025).","journal-title":"Nat. Med."},{"issue":"Suppl. 16","key":"3688_CR26","doi-asserted-by":"publisher","first-page":"abstr 8510","DOI":"10.1200\/JCO.2024.42.16_suppl.8510","volume":"42","author":"TF Burns","year":"2024","unstructured":"Burns, T. F. et al. Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC. J. Clin. Oncol. 42(Suppl. 16), abstr 8510 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3688_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710\u2013721 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3688_CR28","doi-asserted-by":"publisher","first-page":"PR014","DOI":"10.1158\/1535-7163.TARG-23-PR014","volume":"22","author":"PA J\u00e4nne","year":"2023","unstructured":"J\u00e4nne, P. A. et al. Abstract PR014: preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment. Mol. Cancer Ther. 22, PR014 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"3688_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51828-2","volume":"15","author":"MJ Nokin","year":"2024","unstructured":"Nokin, M. J. et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat. Commun. 15, 7554 (2024).","journal-title":"Nat. Commun."},{"key":"3688_CR30","doi-asserted-by":"publisher","first-page":"e15087","DOI":"10.1200\/JCO.2022.40.16_suppl.e15087","volume":"40","author":"J Lu","year":"2022","unstructured":"Lu, J. et al. D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C: human dose prediction and first-in-human (FIH) trial design. J. Clin. Oncol. 40, e15087 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3688_CR31","first-page":"169","volume":"15","author":"ATM Lee","year":"2024","unstructured":"Lee, A. T. M. & Nagasaka, M. Adagrasib in KRYSTAL-12 has not broken the KRAS G12C enigma code of the unspoken 6-month PFS barrier in NSCLC. Lung Cancer (Auckl.) 15, 169\u2013176 (2024).","journal-title":"Lung Cancer (Auckl.)"},{"key":"3688_CR32","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. 384, 2382\u20132393 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3688_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599, 679\u2013683 (2021).","journal-title":"Nature"},{"key":"3688_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11523-024-01055-y","volume":"19","author":"D Brazel","year":"2024","unstructured":"Brazel, D. & Nagasaka, M. Divarasib in the evolving landscape of KRAS G12C inhibitors for NSCLC. Target. Oncol. 19, 297\u2013301 (2024).","journal-title":"Target. Oncol."},{"key":"3688_CR35","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","volume":"24","author":"JI Odegaard","year":"2018","unstructured":"Odegaard, J. I. et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin. Cancer Res. 24, 3539\u20133549 (2018).","journal-title":"Clin. Cancer Res."},{"key":"3688_CR36","doi-asserted-by":"publisher","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","volume":"10","author":"RB Lanman","year":"2015","unstructured":"Lanman, R. B. et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS ONE 10, e0140712 (2015).","journal-title":"PLoS ONE"},{"key":"3688_CR37","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1158\/1078-0432.CCR-19-1324","volume":"25","author":"J Willis","year":"2019","unstructured":"Willis, J. et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin. Cancer Res. 25, 7035\u20137045 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3688_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jtho.2016.11.2235","volume":"12","author":"X Mao","year":"2017","unstructured":"Mao, X. et al. Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. J. Thorac. Oncol. 12, 663\u2013672 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"3688_CR39","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdy009","volume":"29","author":"YS Li","year":"2018","unstructured":"Li, Y. S. et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. Ann. Oncol. 29, 945\u2013952 (2018).","journal-title":"Ann. Oncol."},{"key":"3688_CR40","doi-asserted-by":"publisher","first-page":"741142","DOI":"10.3389\/fonc.2021.741142","volume":"11","author":"Z Tao","year":"2021","unstructured":"Tao, Z. et al. Profiling receptor tyrosine kinase fusions in Chinese breast cancers. Front. Oncol. 11, 741142 (2021).","journal-title":"Front. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03688-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03688-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03688-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:46:43Z","timestamp":1757159203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03688-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3688"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03688-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C.C. reports research funding from GIInovation, AstraZeneca, Champions Oncology, CJ Bioscience, Cyrus, Janssen, Merck Sharp & Dohme, Dong-A ST, Yuhan, ImmuneOncia, Therapex, JINTSbio and Vertical Bio AG; royalties from Champions Oncology, Crown Bioscience, Imagen and PearlRiver Bio GmbH; consulting fees from BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, CJ, Cyrus Therapeutics, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, Merck Sharp & Dohme, Gilead, Amgen, Daiichi Sankyo, Regeneron, Sanofi, AnHeart Therapeutics, Seagen, Harpoon Therapeutics, GlaxoSmithKline and ArriVent; honoraria as an invited speaker from ASCO, AstraZeneca, Guardant, Roche, ESMO, IASLC, Korean Cancer Association, Korean Society of Medical Oncology, Korean Society of Thyroid-Head and Neck Surgery, Korean Cancer Study Group, Novartis, Merck Sharp & Dohme, the Chinese Thoracic Oncology Society, Pfizer and ZaiLab; participation on scientific advisory boards for KANAPH Therapeutic Inc., Bridgebio Therapeutics, Cyrus Therapeutics, Guardant Health, J INTS Bio and Therapex Co. Ltd; stock ownership with TheraCanVac Inc., Gencurix Inc., Bridgebio Therapeutics, KANPH Therapeutic Inc., Cyrus Therapeutics, Interpark Bio Convergence Corp. and J INTS Bio; and other financial or nonfinancial interests with Yonsei University Health System (employment), DAAN Biotherapeutics (founder) and J INTS BIO (member of the board of directors). S.L. reports research funding from AstraZeneca, Hutchison, Bristol Myers Squibb, Hengrui Therapeutics, BeiGene, Roche and Hansoh; consulting fees from AstraZeneca, Hutchison, Simcere, ZaiLab and Yuhan Corporation; honoraria from AstraZeneca, Roche, Hansoh and Hengrui Therapeutics; participation on advisory boards for AstraZeneca, Yuhan Corporation, Inventis Bio, Merck Sharp & Dohme, Simcere Zaiming Pharmaceutical, Shanghai Fosun Pharmaceutical and Phase Therapeutics; and a leadership role with Innovent Biologics. Z.L. reports honoraria from AstraZeneca, Roche, Hansoh and Pfizer. G.R. reports research funding from Bristol Myers Squibb, Roche\/Genentech, AstraZeneca, Merck, Takeda, BeiGene, Pfizer, CBT Pharmaceuticals, Corvus Pharmaceuticals, Novotech, Shanghai Fosun Pharmaceutical Development, Shanghai Henlius Biotech, Five Prime Therapeutics, Suzhou Alphamab, Boehringer Ingelheim, Adagene Inc., Bio-Thera Solutions, ChemoCentryx, Curon Biopharmaceutical, D3 Bio, Inventis Bio, Senz Oncology, Genfleet Therapeutics, GeneQuantum Healthcare, Keythera Pharmaceuticals, LaNova Australia, Medicenna Therapeutics, Minghui Pharmaceutical, Neoleukin Therapeutics, PharmAbcine Australia, RemeGen, Seagen, Surface Oncology, Eucure Biopharma, Janssen Oncology, ImmuGen, Imugene, Therapim, Zentalis and Agenus. Jun Zhang reports participation on advisory boards for Astellas and Shanghai HengRui. H.H.L. reports research funding from MSD, MundiPharma and Novartis; consulting fees from Boehringer Ingelheim, Celgene, Eli Lilly, Illumina, Novartis, Merck Serono, Takeda and George Clinical; honoraria from AbbVie, Bayer, Eisai, Eli Lilly, Guardant Health and Novartis; and support for meeting attendance and\/or travel from Bayer, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis and Pfizer. C.C., J.W., Y.S., Z.F., Q.C., H.W., Jing Zhang and Z.J.C. report employment and stock or stock options with D3 Bio. M.L.J. reports funding to the institution from D3 Bio for the current work; grants to the institution from AbbVie, Adaptimmune, Amgen, Arcus Biosciences, Array BioPharma, ArriVent BioPharma, Artios Pharma, AstraZeneca, Bayer, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, City of Hope National Medical Center, Conjupro Biotherapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech\/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchinson MediPharma, IDEAYA Biosciences, IGM Biosciences, Immuneering Corporation, Immunitas Therapeutics, Immunocore, Impact Therapeutics, Incyte, Janssen, Kartos Therapeutics, LockBody Therapeutics, Loxo Oncology, Memorial Sloan Kettering, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmune Tech, Neovia Oncology, NextPoint Therapeutics, Novartis, Numab Therapeutics, Nuvalent, OncoC4, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals\/Birdie Pharmaceuticals, Shattuck Laboratories, Silicon Therapeutics, Systimmune, Taiho Oncology, Takeda Pharmaceuticals, TCR2 Therapeutics, Tempest Therapeutics, TheRas, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, Vividion, Vyriad and Y-mAbs Therapeutics; consulting fees from AbbVie, Alentis Therapeutics, Amgen, Arcus Biosciences, AstraZeneca, Biohaven Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio Limited, Daiichi Sankyo, Fate Therapeutics, Genentech\/Roche, Gilead Sciences, GlaxoSmithKline, Gritstone Oncology, Hookipa Biotech, Immunocore, Janssen Pharmaceuticals, Lilly, Merck, Mirati Therapeutics, ModeX Therapeutics, Normunity, Novartis, Novocure, Pfizer, Regneron Pharmaceuticals, Revolution Medicines, Sanofi-Aventis, SeaGen, Synthekine, Takeda Pharmaceuticals and Zai Laboratory. T.M. reports research funding from AstraZeneca, Bristol Myers Squibb, G1 Therapeutics, Merck Sharp & Dohme, Merck Serono, Novartis, Pfizer, Roche, SFJ, Takeda and XCovery; consulting fees from AbbVie, ACEA Pharma, Adagen, Alentis Therapeutics, Alpha Biopharma, Amgen, Amoy Diagnostics Co, AnHeart Therapeutics, AVEO Pharmaceuticals, Bayer Healthcare Pharmaceuticals, BeiGene, BerGenBio ASA, Berry Oncology, Boehringer Ingelheim, Blueprint Medicines Corporation, BridgeBio, Bristol Myers Squibb, Bowtie Life Insurance Company Limited, Bridge Biotherapeutics Inc., Covidien LP, C4 Therapeutics Inc., Cirina, CStone Pharmaceuticals, Curio Science, D3 Bio, Da Volterra, Daiichi Sankyo, Eisai, Elevation Oncology, Erasca, F. Hoffmann\u2013La Roche\/Genentech, Fishawack Facilitate, G1 Therapeutics, geneDecode, Gilead Sciences, GLG\u2019s Healthcare, Gritstone Oncology, Guardant Health, HengRui Therapeutics, HiberCell, HutchMed, Ignyta, Illumina, Imagene AI, Incyte Corporation, Inivata, InxMed, IQVIA, Janssen, Lakeshore Biotech, Lilly, Lunit USA, Loxo Oncology, Lucence Health, Medscape\/WebMD, Medtronic, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, MiRXES, MoreHealth, Novartis, Novocure GmbH, Ningbo NewBay Technology Development, Omega Therapeutics, OrigiMed, OSE Immunotherapeutics, PeerVoice, Phanes Therapeutics, Pfizer, PrIME Oncology, Prenetics Global, Puma Biotechnology, Qiming Development (HK), Regen Medtech Holdings, Regeneron Pharmaceuticals, Roche Pharmaceuticals\/Diagnostics\/Foundation One, Sanofi-Aventis, Schr\u00f6dinger, Seagen International GmbH, SFJ Pharmaceutical, Simcere of America, Synergy Research, Summit Therapeutics, Takeda Pharmaceuticals HK, Tigermed, Vertex Pharmaceuticals, Virtus Medical Group, Xencor and Yuhan Corporation; honoraria from ACEA Pharma, Alpha Biopharma, Amgen, Amoy Diagnostics, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Daz Group, Fishawack Facilitate, InMed Medical Communication, Janssen Pharmaceutica NV, Jiahui Holdings, LiangYiHui Healthcare, Lilly, Lucence Health, MD Health Brazil, Medscape, Merck Pharmaceuticals HK, Merck Sharp & Dohme, MiRXES, Novartis, OrigiMed, P. Permanyer SL, PeerVoice, Physicians\u2019 Education Resource, Pfizer, PrIME Oncology, Research to Practice, Roche Pharmaceuticals\/Diagnostics\/Foundation One, Sanofi-Aventis, Shanghai BeBirds Translation & Consulting, Taiho Pharmaceutical, Takeda Oncology, and Touch Independent Medical Education; support for meeting attendance and\/or travel from Novartis, Roche, Pfizer, AstraZeneca, Daiichi Sankyo, Boehringer Ingelheim, MiRXES, Bristol Myers Squibb, Merck Sharp & Dohme, AbbVie, ZaiLab and Liangyihui; participation in advisory boards for AbbVie, ACEA Pharma, Amgen, AstraZeneca, Alentis Therapeutics AG, BerGenBio ASA, Berry Oncology, Blueprint Medicines Corporation, Boehringer Ingelheim, Bowtie Life Insurance, Bristol Myers Squibb, C4 Therapeutics, Covidien LP, CStone Pharmaceuticals, Curio Science, D3 Bio, Daiichi Sankyo, Eisai, Erasca, Fishawack Facilitate, G1 Therapeutics, Gilead Sciences, Gritstone Oncology, Guardant Health, geneDecode (uncompensated), Hengrui Therapeutics, HutchMed, Ignyta, Incyte Corporation, Imagene AI, Inivata, IQVIA, Janssen, Lakeshore Biotech, Lilly, Loxo Oncology, Lunit, Merck Serono, Merck Sharp & Dohme, Mirati Therapeutics, MiRXES Group, Novartis, OrigiMed, Phanes Therapeutics, Pfizer, Prenetics Global, Puma Biotechnology, Roche\/Genentech, Regeneron Pharmaceuticals, Sanofi-Aventis R&D, SFJ Pharmaceutical, Simcere of America, Simcere Zaiming, Takeda, Vertex Pharmaceuticals, Virtus Medical Group, Xencor and Yuhan Corporation; leadership role for AstraZeneca, HutchMed, Aurora, Epoch Biosciences and Insighta; stock or stock options with AstraZeneca, Aurora Tele-Oncology, Biolidics, HutchMed, Prenetics Global, D3 Bio, Lunit, Bowtie Life Insurance, Lakeshore Biotech, Loxo Oncology, Virtus Medical Group, Yinson Capital, Phanes Therapeutics, Insighta and Alentis Therapeutics AG. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}